AI In Drug Discovery 2021 - Virtual Conference
AI In Drug Discovery 2021 - Virtual Conference
15th March to 16th March 2021,
Online Virtual Event , United Kingdom
SMi is proud to announce the 2nd annual AI in Drug Discovery virtual conference taking place on 15th and 16th March 2021
With the global Artificial Intelligence (AI) in Drug Discovery Market size expected to exceed $3,900 million by 2027, this year’s agenda will encompass key drivers leading the way into a shorter, cheaper, and more successful R&D era. The conference will cover hot topics including; machine learning techniques for improving early drug discovery, effective prediction of ADMET properties, data quality, and innovative applications of AI for undruggable targets.
This year’s event will focus on 4 key themes: machine learning and automation for improved drug discovery pipelines; effective prediction of compound properties; data robustness and curation; innovative use of AI for rare and undruggable diseases. The agenda will highlight key case studies across these themes, uncovering key developments in pharma of data optimization and to aid therapeutic discovery. Real-world examples of AI in structure-based drug design and patient relevant data will be explored.
This two-day agenda offers you peer-to-peer networking with industry experts including directors and heads of informatics, data & AI, molecular design, and computational chemistry, to explore the latest developments in the industry, regulatory updates, and case studies from leading pharmaceutical and biotechnology companies.
source: http://www.smi-online.co.uk/pharmaceuticals/uk/conference/drug-discovery
If you have any questions about this news, please do not hesitate to contact us.
Join Our Newsletter for Free
Latest News
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT).
LEARN MOREPfizer Acquires Amplyx Pharmaceuticals
Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.
LEARN MOREJanux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company).
LEARN MORE